ArticleInternational journal of clinical and experimental medicine2015
The tumor protection effect of high-frequency administration of whole tumor cell vaccine and enhanced efficacy by the protein component from Agrocybe aegerita.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor.ACS nano · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whole tumor cell vaccines have been widely studied and elicits limited immune responses because of the poor immunogenicity. In the present study, we discovered that high-frequency administration of irradiated whole tumor cell vaccine triggered rejection of tumor cells (90% or 100% of the mice that were vaccinated with irradiated H22 cells or S180 respectively were protected), and provided cross-protection and long-term anti-tumor immunity in BALB/c mouse models. The antitumor activity required CD4+, CD8+ T cells and macrophage that was proved in the nude mice and cell depletion mouse models. The adoptive transfer experiment suggested that repeated whole tumor cell vaccination successfully stimulated the anti-tumor response by activation of the immune cells. A high immunization frequency within a short period of time and the presence of glycosylated molecules and nucleic acids on the surface of intact tumor cells were crucial for the successful prevention of tumor growth by whole tumor cell vaccines. Moreover, Yt, the protein component from fungus Agrocybe aegerita, increased whole tumor cell vaccine-mediated tumor rejection and cross-protection effect. These data indicated that the frequency of administration of whole tumor cell vaccines was of critical importance for the efficacy, which needed to be integrated into vaccine strategies for producing potential vaccines.
Indexed as
Identifiers
26221228PMC4509173W1010660181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.